NASDAQ:BTTX Better Therapeutics (BTTX) Stock Forecast, Price & News $0.73 0.00 (0.00%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$0.70▼$0.7850-Day Range$0.64▼$1.4652-Week Range$0.59▼$2.80Volume185,297 shsAverage Volume185,051 shsMarket Capitalization$23.16 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Better Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside858.9% Upside$7.00 Price TargetShort InterestHealthy4.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$447,794 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector572nd out of 985 stocksHealth Services Industry8th out of 13 stocks 3.3 Analyst's Opinion Consensus RatingBetter Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Better Therapeutics has a forecasted upside of 858.9% from its current price of $0.73.Amount of Analyst CoverageBetter Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.79% of the float of Better Therapeutics has been sold short.Short Interest Ratio / Days to CoverBetter Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Better Therapeutics has recently increased by 19.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBetter Therapeutics does not currently pay a dividend.Dividend GrowthBetter Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTTX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for BTTX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Better Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Better Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $447,794.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders59.40% of the stock of Better Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.46% of the stock of Better Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Better Therapeutics are expected to grow in the coming year, from ($1.33) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Better Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Better Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Better Therapeutics (NASDAQ:BTTX) StockBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.Read More Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTTX Stock News HeadlinesMay 17, 2023 | insidermonkey.comBetter Therapeutics, Inc. (NASDAQ:BTTX) Q1 2023 Earnings Call TranscriptMay 16, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Better Therapeutics, Inc. (BTTX)June 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 11, 2023 | msn.comBetter Therapeutics: Q1 Earnings InsightsMay 11, 2023 | markets.businessinsider.comChardan Capital Remains a Buy on Better Therapeutics, Inc. (BTTX)May 11, 2023 | msn.comBetter Therapeutics GAAP EPS of -$0.39May 11, 2023 | finance.yahoo.comBetter Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | msn.comBetter Therapeutics's Earnings: A PreviewJune 6, 2023 | Vector Vest (Ad)Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 4, 2023 | finance.yahoo.comBetter Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023April 15, 2023 | americanbankingnews.comLake Street Capital Lowers Better Therapeutics (NASDAQ:BTTX) Price Target to $5.00April 13, 2023 | americanbankingnews.comGeoffrey M. Parker Buys 303,030 Shares of Better Therapeutics, Inc. (NASDAQ:BTTX) StockApril 13, 2023 | americanbankingnews.comBetter Therapeutics, Inc. (NASDAQ:BTTX) Insider Frank Karbe Buys 242,424 Shares of StockApril 13, 2023 | msn.comBetter Therapeutics up 8% on raising ~$6.5MApril 8, 2023 | seekingalpha.comBetter Therapeutics announces equity offering to raise $6.5MApril 8, 2023 | americanbankingnews.comFY2023 EPS Estimates for Better Therapeutics, Inc. (NASDAQ:BTTX) Increased by AnalystApril 6, 2023 | finance.yahoo.comBetter Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the UpgradeApril 6, 2023 | msn.comBetter Therapeutics launches private placement to raise $6.5MApril 6, 2023 | finance.yahoo.comBetter Therapeutics Announces $6.5MM Private PlacementApril 4, 2023 | americanbankingnews.comBetter Therapeutics (NASDAQ:BTTX) Downgraded by Lifesci CapitalApril 3, 2023 | americanbankingnews.comBetter Therapeutics (NASDAQ:BTTX) PT Lowered to $9.00 at Chardan CapitalApril 1, 2023 | seekingalpha.comBetter Therapeutics, Inc. (BTTX) Q4 2022 Financial Results Conference Call TranscriptApril 1, 2023 | marketwatch.comY-mAbs Therapeutics Shares Soar 70% After Surprise 4Q ProfitMarch 30, 2023 | msn.comBetter Therapeutics GAAP EPS of -$0.37 beats by $0.13March 30, 2023 | marketwatch.comNatural Killer Cells Therapeutics Market Top Players by 2031March 30, 2023 | finance.yahoo.comBetter Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 29, 2023 | benzinga.comA Preview Of Better Therapeutics's EarningsSee More Headlines BTTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTTX Company Calendar Today6/06/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Health services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTTX CUSIPN/A CIK1832415 Webmcacquisition.com Phone415-887-2311FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+858.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,082.89% Return on Assets-156.14% Debt Debt-to-Equity Ratio1.61 Current Ratio0.62 Quick Ratio0.62 Sales & Book Value Annual Sales$10,000.00 Price / Sales2,316.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-18.25Miscellaneous Outstanding Shares31,731,000Free Float12,883,000Market Cap$23.16 million OptionableNot Optionable Beta1.57 Key ExecutivesMr. David P. Perry M.B.A. (Age 55)Co-Founder & Exec. Chairman Comp: $194.71kDr. Mark A. Berman M.D. (Age 48)Chief Medical Officer Comp: $576.38kMs. Kristin Wynholds (Age 51)Chief Product Officer Comp: $586.5kMr. Frank L. Karbe (Age 55)CEO, Pres & Director Mr. Mark Heinen (Age 54)Head of Fin. & Interim CFO Mr. Andres CamachoSr. VP of Technology & Head of EngineeringMr. Thiago Licias De OliveiraChief People OfficerMs. Diane Gomez-ThinnesChief Commercial OfficerMore ExecutivesKey CompetitorsUpHealthNYSE:UPHBabylonNYSE:BBLNReunion NeuroscienceNASDAQ:REUNHarpoon TherapeuticsNASDAQ:HARPEquilliumNASDAQ:EQView All CompetitorsInsiders & InstitutionsElder GrangerBought 600 shares on 5/16/2023Total: $522.00 ($0.87/share)Farallon Capital Management LLCSold 114,514 shares on 5/15/2023Ownership: 2.931%Geoffrey M ParkerBought 303,030 shares on 4/10/2023Total: $248,484.60 ($0.82/share)Frank KarbeBought 242,424 shares on 4/10/2023Total: $198,787.68 ($0.82/share)Frank KarbeBought 50,000 shares on 9/15/2022Total: $104,500.00 ($2.09/share)View All Insider TransactionsView All Institutional Transactions BTTX Stock - Frequently Asked Questions Should I buy or sell Better Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares. View BTTX analyst ratings or view top-rated stocks. What is Better Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 1-year price objectives for Better Therapeutics' stock. Their BTTX share price forecasts range from $5.00 to $9.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 858.9% from the stock's current price. View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts. How have BTTX shares performed in 2023? Better Therapeutics' stock was trading at $1.1050 on January 1st, 2023. Since then, BTTX shares have decreased by 33.9% and is now trading at $0.73. View the best growth stocks for 2023 here. Are investors shorting Better Therapeutics? Better Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 154,600 shares, an increase of 19.1% from the April 30th total of 129,800 shares. Based on an average daily volume of 128,100 shares, the short-interest ratio is presently 1.2 days. Approximately 4.8% of the company's shares are sold short. View Better Therapeutics' Short Interest. When is Better Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our BTTX earnings forecast. What is Better Therapeutics' stock symbol? Better Therapeutics trades on the NASDAQ under the ticker symbol "BTTX." Who are Better Therapeutics' major shareholders? Better Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (2.93%). Insiders that own company stock include Andrew J Armanino, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark Heinen and Risa J Lavizzo-Mourey. View institutional ownership trends. How do I buy shares of Better Therapeutics? Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Better Therapeutics' stock price today? One share of BTTX stock can currently be purchased for approximately $0.73. How much money does Better Therapeutics make? Better Therapeutics (NASDAQ:BTTX) has a market capitalization of $23.16 million and generates $10,000.00 in revenue each year. The company earns $-39,760,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. How can I contact Better Therapeutics? Better Therapeutics' mailing address is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. The official website for the company is mcacquisition.com. The company can be reached via phone at 415-887-2311 or via email at mcac@icrinc.com. This page (NASDAQ:BTTX) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.